...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drug discovery today >Glucocorticoid-resistant asthma and novel anti-inflammatory drugs
【24h】

Glucocorticoid-resistant asthma and novel anti-inflammatory drugs

机译：糖皮质激素抵抗性哮喘和新型抗炎药

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Synthetic glucocorticoids are among the most commonly used prescription medicines. Nevertheless, their clinical efficacy is accompanied by dose- and indication-limiting acute and chronic adverse effects. Intrinsic or acquired resistance to glucocorticoid actions may also limit clinical efficacy. In chronic inflammatory conditions there has been a considerable focus on understanding mechanism(s) of resistance in cells with a primary immune and/or inflammatory function. However, it has become increasingly accepted that a substantial part of the efficacy of glucocorticoid treatments derives from actions on 'structural' cell types (smooth muscle, fibroblasts, epithelia). In this article we review the mechanism of action of glucocorticoids on structural cells and contrast knowledge of resistance mechanisms between structural and inflammatory cell types, using asthma as an exemplar chronic inflammatory condition associated with glucocorticoid resistance.
机译：合成糖皮质激素是最常用的处方药之一。然而，它们的临床疗效伴随着剂量和适应症的急性和慢性不良反应。对糖皮质激素作用的内在或获得性耐药也可能限制临床疗效。在慢性炎性疾病中，相当大的注意力集中在理解具有主要免疫和/或炎性功能的细胞中的抗性机制。然而，越来越多的人接受糖皮质激素治疗功效的很大一部分来自对“结构性”细胞类型（平滑肌，成纤维细胞，上皮细胞）的作用。在本文中，我们将哮喘作为与糖皮质激素抵抗相关的典型慢性炎症病状，回顾了糖皮质激素对结构细胞的作用机制，并对比了结构性和炎症细胞类型之间的耐药机制知识。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号